9.8  -0.2 (-2%)		12-27 00:00
Open: 10.05 High: 10.15 Volume: 289,188		Pre. Close: 10 Low: 9.69 Market Cap: 605(M)

Short term
Mid term
Targets	6-month :	11.64	1-year :	11.85
Resists	First :	9.97	Second :	10.14
Pivot price	9.8
Supports	First :	9.68	Second :	8.06
MAs	MA(5) :	9.8	MA(20) :	9.8
	MA(100) :	10.79	MA(250) :	10.34
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	23.9	D(3) :	23.9
RSI	RSI(14): 35.1
52-week	High :	15.04	Low :	9.64

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ FSII ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

As of December 23, 2021, FS Development Corp. II was acquired by FS Development Corp. II, in a reverse merger transaction. FS Development Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in San Francisco, California.

Thu, 26 Oct 2023
FS2/23 – Artificial Intelligence and Machine Learning - Bank of England

Mon, 30 Jan 2023
STM wins two contracts to support Nato's INTEL-FS2 projects - Army Technology

Tue, 04 Jan 2022
White & Case Advises FS Development Corp. II on Business Combination with Pardes Biosciences - White & Case LLP

Mon, 27 Dec 2021
Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat ... - GlobeNewswire

Wed, 22 Dec 2021
Startup with potential Covid-fighting pill eyes $300M SPAC deal - San Francisco Business Times - The Business Journals

Tue, 21 Dec 2021
Pardes to go public, says COVID-19 antiviral pill does not need booster - Yahoo Movies UK

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Financial Services
Industry: Shell Companies
Shares Out	21 (M)
Shares Float	17 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	40 (K)
Shares Short P.Month	17 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.35
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-28.01
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.